Literature DB >> 11768628

Clinical characteristics of neuroleptic-induced parkinsonism.

S Hassin-Baer1, P Sirota, A D Korczyn, T A Treves, B Epstein, H Shabtai, T Martin, Y Litvinjuk, N Giladi.   

Abstract

In order to characterize the clinical spectrum of neuroleptic-induced parkinsonism (NIP), we studied a population of consecutive psychiatric in-patients treated with neuroleptics for at least two weeks, who were diagnosed by their psychiatrist as having parkinsonism. Parkinsonism was confirmed by a movement disorders specialist who performed neurological assessment including the motor examination and the activities of daily living (ADL) sections of the Unified Parkinson's Disease Rating Scale (UPDRS), and the Hoehn and Yahr (H&Y) staging. Seventy-five patients (54 males), aged 46 +/- 13 years (range 21 to 73 years) were included in the analysis. The mean duration of neuroleptic therapy was 15 +/- 12 years, while 61% were treated for more than 10 years. Most of the patients (n = 66, 88%) were scored as H&Y stage 2.5 or less. Rest tremor was present in 44% of the patients, and usually persisted in action. Forty-one patients (61%) had symmetrical involvement. Parkinsonian signs were significantly more common and pronounced in the upper in comparison with the lower limbs (p = 0.0001). Gait disturbances were mild and freezing of gait was very rare (n = 2). Neither age nor duration of therapy or their interaction affected the total motor score or any of the motor sub-scores. In conclusion, NIP differs from PD for more bilateral involvement with relative symmetry, and by affecting upper limbs more often than the lower ones. NIP tends to be associated with the triad of bradykinesia, tremor and rigidity while PD tends to involve gait and posture more often. NIP develops unrelated to duration of neuroleptic treatment or age of the patient, suggesting an individual predisposition to blockage of the dopaminergic receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768628     DOI: 10.1007/s007020100006

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  19 in total

1.  Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients.

Authors:  Lior Greenbaum; Robert C Smith; Mordechai Lorberboym; Anna Alkelai; Polina Zozulinsky; Tzuri Lifschytz; Tzuri Lifshytz; Yoav Kohn; Ruth Djaldetti; Bernard Lerer
Journal:  Psychopharmacology (Berl)       Date:  2011-09-24       Impact factor: 4.530

2.  Drug-induced parkinsonism.

Authors:  Frandy Susatia; Hubert H Fernandez
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

3.  The nature of bradykinesia in schizophrenia treated with antipsychotics.

Authors:  Michael P Caligiuri; Hans-Leo Teulings; Charles E Dean; James B Lohr
Journal:  Psychiatry Res       Date:  2019-01-15       Impact factor: 3.222

Review 4.  Approach to diagnosis of Parkinson disease.

Authors:  Christopher Frank; Giovanna Pari; John P Rossiter
Journal:  Can Fam Physician       Date:  2006-07       Impact factor: 3.275

5.  Tremor analysis separates Parkinson's disease and dopamine receptor blockers induced parkinsonism.

Authors:  Aasef G Shaikh
Journal:  Neurol Sci       Date:  2017-02-22       Impact factor: 3.307

6.  Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease.

Authors:  Francisco J Diaz-Corrales; Salome Sanz-Viedma; David Garcia-Solis; Teresa Escobar-Delgado; Pablo Mir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-28       Impact factor: 9.236

7.  Prediction of Parkinson's disease subsequent to severe depression: a ten-year follow-up study.

Authors:  Uwe Walter; Robert Heilmann; Lara Kaulitz; Tino Just; Bernd Joachim Krause; Reiner Benecke; Jacqueline Höppner
Journal:  J Neural Transm (Vienna)       Date:  2014-09-14       Impact factor: 3.575

8.  Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.

Authors:  Michele Tinazzi; Angelo Antonini; Tommaso Bovi; Isabella Pasquin; Maria Steinmayr; Giuseppe Moretto; Antonio Fiaschi; Sarah Ottaviani
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

9.  Olfactory Impairment Predicts Underlying Dopaminergic Deficit in Presumed Drug-Induced Parkinsonism.

Authors:  James F Morley; Gang Cheng; Jacob G Dubroff; Stephanie Wood; Jayne R Wilkinson; John E Duda
Journal:  Mov Disord Clin Pract       Date:  2016-11-28

Review 10.  Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review.

Authors:  Sharadha Wisidagama; Abiram Selladurai; Peter Wu; Marco Isetta; Jordi Serra-Mestres
Journal:  Medicines (Basel)       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.